Date | Price Target | Rating | Analyst |
---|---|---|---|
9/26/2024 | $84.00 → $74.00 | Neutral → Sell | UBS |
9/18/2024 | $100.00 | Neutral → Buy | BTIG Research |
9/9/2024 | $90.00 | Neutral | JP Morgan |
8/6/2024 | $100.00 | Buy | Stifel |
5/30/2024 | $87.00 | Neutral | Goldman |
2/15/2024 | $100.00 | Buy | HSBC Securities |
2/12/2024 | $66.00 → $88.00 | Sell → Neutral | UBS |
11/30/2023 | $80.00 | Hold | Jefferies |
11/27/2023 | $86.00 → $66.00 | Neutral → Sell | UBS |
9/19/2023 | $82.00 | Buy | Citigroup |
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
GE HealthCare (NASDAQ:GEHC) today announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC's (Intelligent Ultrasound) clinical artificial intelligence (AI) software business for total consideration of approximately $51 million. Intelligent Ultrasound is a leader in integrated AI-driven image analysis tools designed to make ultrasound smarter and more efficient. GE HealthCare plans to incorporate these solutions across the ultrasound portfolio, strengthening its capabilities with technology that helps improve workflows and enhance ease-of-use for the benefit of clinicians and patients.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PFE CALL SWEEP BEARISH 07/19/24 $28.00 $72.8K 28.1K 2.7K MRK CALL SWEEP BEARISH 07/19/24 $140.00 $78.
The U.S. Supreme Court has supported 21 pharmaceutical and medical equipment companies, led by AstraZeneca Plc (NYSE:AZN), in a lawsuit accusing them of funding terrorism that harmed American troops and civilians in Iraq. The justices dismissed a lower court’s ruling that had allowed the case to proceed, directing the court to reconsider the lawsuit. The plaintiffs allege that major U.S. and European pharmaceutical and device manufacturers, including Pfizer Inc (NYSE:PFE), GE Healthcare USA, a unit of GE Healthcare Technologies Inc (NASDAQ:GEHC), Johnson & Johnson (NYSE:JNJ), and F. Hoffmann-La Roche (OTC:RHHBY), provided corrupt payments to the Hezbollah-sponsored militia group Jaysh
Today Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (NASDAQ:GEHC) announced HHNM as the first location in the United States to install GE HealthCare's latest Allia Image Guided System (IGS) Pulse, which was designed to provide exceptional image quality and improve workflow for the diagnosis and treatment of cardiovascular diseases (CVD). HHNM will use the Allia IGS Pulse system in its cardiac electrophysiology (EP) lab to plan, guide and monitor the outcomes of electrophysiological procedures, such as cardiac ablations, cardiac catherizations, transcatheter aortic valve replacements, balloon and coronary angioplasties and more.
Innovative Suite Combines Live Medical Imaging, 3D Anatomy Visualization, And Advanced Imaging Technologies With Remote Collaboration Capabilities
GE HealthCare Techs's (NYSE:GEHC) short percent of float has risen 12.46% since its last report. The company recently reported that it has 11.64 million shares sold short, which is 3.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.29 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short i
On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said he is making good money in NVIDIA Corporation (NASDAQ:NVDA) and believes he will continue to do so. The chipmaker giant has seen an astounding 186% surge since the end of May 2023, fueled by skyrocketing demand for chips in artificial intelligence development. Stephanie Link of Hightower said she likes GE HealthCare Technologies Inc. (NASDAQ:GEHC). On April 30, GE Healthcare Technologies reported first-quarter sales of $4.6 billion, down 1% Y/Y, and were approximately flat on an Organic basis, with decreased volume partially offset by positive price, missing the consensus of $4.8 billion. Don't forget
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
Company updates medium-term framework with progress toward financial goals; increases quarterly cash dividend by approximately 17% GE HealthCare (NASDAQ:GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance. The event will feature presentations from GE HealthCare President and CEO Peter Arduini, GE HealthCare Vice President and CFO Jay Saccaro, and other members of the management team, who will discuss the company's vision and precision care strategy, progress since its spin-off from General Electric Company in 2023, and key growth areas.
Revenue growth was 1% year-over-year; Organic revenue growth* was 1% Net income margin was 9.7% versus 7.8% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 16.3% versus 15.4% Diluted earnings per share (EPS) were $1.02 versus $0.83 for the prior year; Adjusted EPS* was $1.14 versus $0.99 Cash flow from operating activities was $742 million versus $650 million for the prior year; Free cash flow* was $651 million versus $570 million Company raises low end of full-year 2024 Adjusted EBIT margin* and Adjusted EPS* guidance with continued execution; trending toward the lower end of Organic revenue growth* range GE HealthCare (NASDAQ:GEHC) today repor
GE HealthCare (NASDAQ:GEHC) will announce its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions inno
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2024 payable on November 15, 2024 to all shareholders of record as of October 18, 2024. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, c
Revenues were flat year-over-year; Organic revenue growth* was 1% Net income margin was 8.9% versus 8.7% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.3% versus 14.8% Diluted earnings per share (EPS) were $0.93 versus $0.91 for the prior year; Adjusted EPS* was $1.00 versus $0.92 Cash flow from operating activities was $(119) million versus $(67) million for the prior year; Free cash flow* was $(182) million versus $(136) million Company updates full-year guidance for Organic revenue growth* and Adjusted EBIT margin* GE HealthCare (NASDAQ:GEHC) today reported financial results for the second quarter ended June 30, 2024. GE HealthCare
GE HealthCare (NASDAQ:GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, will announce its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the second quarter of 2024 payable on August 15, 2024 to all shareholders of record as of July 19, 2024. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, con
Revenues declined 1% year-over-year; Organic revenue growth* was approximately flat Net income margin was 8.0% versus 7.9% for the prior year; Adjusted Earnings Before Interest and Taxes (EBIT) margin* was 14.7% versus 14.1% Diluted earnings per share (EPS) were $0.81 versus $0.41 for the prior year; Adjusted EPS* was $0.90 versus $0.85 Cash flow from operating activities was $419 million versus $468 million for the prior year; Free cash flow* was $274 million versus $325 million; repaid $150 million of debt in January 2024 Reaffirming full year 2024 guidance GE HealthCare (NASDAQ:GEHC), a leading global precision care innovator, today reported financial results for the firs
GE HealthCare (NASDAQ:GEHC), a leader in precision care innovation, will announce its first quarter 2024 financial results before the market opens on Tuesday, April 30, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay will also all be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digit
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the first quarter of 2024 payable on May 15, 2024 to all shareholders of record as of April 19, 2024. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connec
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy
UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $74.00 from $84.00 previously
BTIG Research upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00
JP Morgan initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $90.00
Stifel initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $100.00
Goldman initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $87.00
HSBC Securities initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $100.00
UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $88.00 from $66.00 previously
Jefferies initiated coverage of GE HealthCare with a rating of Hold and set a new price target of $80.00
UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $66.00 from $86.00 previously
Citigroup initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $82.00
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
424B3 - GE HealthCare Technologies Inc. (0001932393) (Filer)
FWP - GE HealthCare Technologies Inc. (0001932393) (Subject)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
10-Q - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
424B3 - GE HealthCare Technologies Inc. (0001932393) (Filer)
FWP - GE HealthCare Technologies Inc. (0001932393) (Subject)
Company updates medium-term framework with progress toward financial goals; increases quarterly cash dividend by approximately 17% GE HealthCare (NASDAQ:GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance. The event will feature presentations from GE HealthCare President and CEO Peter Arduini, GE HealthCare Vice President and CFO Jay Saccaro, and other members of the management team, who will discuss the company's vision and precision care strategy, progress since its spin-off from General Electric Company in 2023, and key growth areas.
Published in the Journal of Clinical Anesthesia, results from the two-phase, 250 patient pilot study show clinicians found a majority (82%) of the alarms from the wireless and wearable Portrait Mobile monitoring solution to be informative or useful to optimize patient care in medical-surgical units.1 Study findings suggest that continuous monitoring helps provide critical information to clinicians, enabling them to intervene effectively before a patient deteriorates. Undetected patient deterioration, particularly post-surgery, can lead to hazardous yet preventable consequences, with 30-day mortality after surgery representing the third leading cause of death globally.2 GE HealthCa
New MRI technology aims to advance neuroimaging and biomarker research GE HealthCare (NASDAQ:GEHC) has received FDA 510(k) clearance for its innovative SIGNA™ MAGNUS,i a 3.0T high-performance, head-only magnetic resonance imaging (MRI) scanner. This system offers new capabilities for both clinical imaging and neuroscience with the potential to aid in the detection of neurological, oncological, and psychiatric conditions. The FDA clearance of SIGNA MAGNUS underscores the advances made by GE HealthCare in neuroimaging. It features an innovative asymmetrical, high-efficiency, head-only gradient coil design, which achieves higher gradient performance due to its reduced inner diameter, spe
Factors impacting today's critical shortage of radiologic technologists include clinician burnout, the impact of COVID and COVID-related policies, and demand for radiologic technologists outpacing today's number of trained clinicians. GE HealthCare and AMN Healthcare are working together to enable training and development of the next generation of radiologic technologists to help address this critical clinician shortage and support healthcare providers' clinical staffing needs. GE HealthCare (NASDAQ:GEHC) today announced an initiative with AMN Healthcare aimed at helping address the critical shortage of radiologic technologists (rad tech) in the healthcare industry. This initiative hel
Collaboration will leverage GE HealthCare's legacy and scale of imaging innovation and RadNet's DeepHealth AI-powered clinical and workflow solutions to further the innovation, commercialization, and adoption of AI in imaging.Together, GE HealthCare and RadNet's DeepHealth aim to create SmartTechnology™ solutions that harness the power of AI to help redefine radiology workflows and address key challenges across the imaging value chain to improve speed, clinical accuracy, operational efficiency, and elevate patient care.To demonstrate the promise of this strategic relationship, the collaboration will first work to bring together DeepHealth's AI-powered SmartMammo™ 1 solution with GE HealthCar
GE HealthCare Technologies Inc. (NASDAQ:GEHC) (the "Company" or "GE HealthCare") announced today the pricing of the previously announced secondary underwritten public offering (the "Offering") of 13,281,302 shares of its common stock (the "GEHC Shares"). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closing of the Offering, GE Aerospace (General Electric Company) is expected to exchange the GEHC Shares for indebtedness of GE Aerospace held by Morgan Stanley Bank, N.A. (the "MS Lender"), an affiliate of Morgan Stanley & Co. LLC,
GE HealthCare Technologies Inc. (NASDAQ:GEHC) (the "Company" or "GE HealthCare") announced today the launch of a secondary underwritten public offering (the "Offering") of 13,281,302 shares of its common stock (the "GEHC Shares"). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closing of the Offering, GE Aerospace (General Electric Company) is expected to exchange the GEHC Shares for indebtedness of GE Aerospace held by Morgan Stanley Bank, N.A. (the "MS Lender"), an affiliate of Morgan Stanley & Co. LLC, the selling stockholder
GE HealthCare (NASDAQ:GEHC) will host its Investor Day on Thursday, November 21, 2024, at Nasdaq MarketSite in New York, NY, where its management team will present its growth strategies, technology portfolio, and vision for its businesses. A technology showcase will follow the presentations for in-person attendees. Registration is required. The live webcast will be available at https://investor.gehealthcare.com/news-events/events.The press release, presentation, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and
Revenue growth was 1% year-over-year; Organic revenue growth* was 1% Net income margin was 9.7% versus 7.8% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 16.3% versus 15.4% Diluted earnings per share (EPS) were $1.02 versus $0.83 for the prior year; Adjusted EPS* was $1.14 versus $0.99 Cash flow from operating activities was $742 million versus $650 million for the prior year; Free cash flow* was $651 million versus $570 million Company raises low end of full-year 2024 Adjusted EBIT margin* and Adjusted EPS* guidance with continued execution; trending toward the lower end of Organic revenue growth* range GE HealthCare (NASDAQ:GEHC) today repor
Application goes beyond data aggregation to help clinicians quickly see a longitudinal view of their patient's history, spotlighting disease progression and helping to inform proactive interventions Tampa General Hospital and UT Southwestern Medical Center to be early evaluators of CareIntellect for Oncology Application is the first within GE HealthCare's new CareIntellect offering of clinical and operational applications, built to reduce provider integration burden and increase adoption speed for new applications GE HealthCare (NASDAQ:GEHC) today announced CareIntellect for Oncology, a new cloud-first application that brings together multi-modal patient data from disparate systems i